On March 26, 2025, Merck and Roche announced the official signing of an agreement between the two companies regarding the use of Terbotinib (Topicorn)^®）We have reached cooperation in the commercialization of the Chinese Mainland market. Both sides will fully integrate their respective advantageous resources and promote the benefits of terbotinib to more peopleMETex 14 jumping mutation in locally advanced or metastatic non-small cell lung cancer in adult patients.

Lung cancer is a malignant tumor with high incidence rate and mortality worldwide, of which non-small cell lung cancer accounts for about 85%-90%.METex 14, as one of the driving genes for advanced non-small cell lung cancer, has an incidence rate of approximately 1% -4% in non-small cell lung cancer patientsAnd due to limited treatment options and poor clinical prognosis, there is a huge unmet clinical demand.

Zhang Wei, Managing Director of Merck China Healthcare, stated:

We are very happy to have reached this strategic cooperation with Roche to jointly promote the commercialization of Tepotini in the Chinese Mainland market. As an innovative lung cancer treatment drug, tepotinib has demonstrated significant clinical potential. Merck has always been committed to introducing innovative drugs into China, and this cooperation is our practiceAn important step towards' working together for the patient '. We look forward to accelerating the accessibility of Roche in China and benefiting patients through our strong partnership with Roche. In the future, Merck will actively explore innovative cooperation models to bring more treatment options to Chinese patients and help achieve the grand goal of 'Healthy China 2030'.

Roche Pharmaceuticals China President Bian Xin pointed out:

We are delighted to have reached this collaboration with Merck, which will enable us to extend the targeted therapy for Roche lung cancer beyond its original scopeALK+, NTRK/ROS1+are further extended to METex 14 jump mutations, benefiting more patients. The number of lung cancer patients in China is huge, and there is a huge unmet clinical demand. Roche has been deeply involved in the field of lung cancer for many years, always striving to promote standardized diagnosis and treatment of lung cancer. In the future, Roche will continue to accelerate the landing of global original research and innovative drugs in China, actively introduce innovative products with pipeline synergy and excellent commercial value in China, work together with all parties to complement each other's advantages, provide more effective treatment options for Chinese patients, and help them achieve higher quality longevity.

Professor Wu Yilong from Guangdong Provincial People's Hospital stated:

As a clinical researcher who has been deeply involved in the field of lung cancer for decades, I have always believed that promoting the landing of innovative drugs in China and benefiting more Chinese patients is the mission of medical work. The strategic cooperation between Roche and Merck on tepotinib is a vivid practice of this mission——Through strong alliances, improving the accessibility of innovative drugs among Chinese patients and enabling more patients to enjoy better diagnosis and treatment is not only a win-win situation at the commercial level, but also a positive response to the 'Healthy China 2030' strategy.

About Merck

Merck is a technology company that focuses on three major fields: life sciences, healthcare, and electronic technology. Global Super62000 employees serve Merck, bringing positive impact to millions of people's lives by creating more enjoyable and sustainable lifestyles. In 2024, Merck's total sales in 65 countries/regions reached 21.2 billion euros. Scientific exploration and responsible corporate spirit have always been the key to Merck's technological progress, and the secret to Merck's vitality since 1668. The Merck family, as the founders of the company, still holds the majority of Merck's shares. We are called "Merck" globally, except for the United States and Canada. Merck's three major fields: healthcare, life sciences, and electronics are respectively referred to as "EMD Serono", "MilliporeSigma", and "EMD Electronics" in these two countries. Merck has a development history of over 90 years in China and currently has nearly 4500 employees. It has 21 registered companies in Beijing, Shanghai, Wuxi, Suzhou, Nantong, Hong Kong and other places.

About Roche

Roche was founded inIn 1896, headquartered in Basel, Switzerland, with a history of nearly 130 years, it was a leader in biotechnology companies and in vitro diagnostics. As one of the enterprises engaged in industrial production of original drugs, Roche is committed to continuously exploring the transformation of cutting-edge science into disease diagnosis and treatment drugs, saving lives and improving human quality of life. Roche has differentiated drugs in the fields of anti-tumor, immunology, anti infection, ophthalmology, and neuroscience.
Roche Pharmaceuticals China was founded inIn 1994, as the first multinational enterprise to settle in Shanghai Zhangjiang High tech Park, Roche Pharmaceuticals held a large market share in key fields such as anti-tumor, anti infection, neuroscience, and ophthalmology. At present, Roche Pharmaceuticals has 29 products in China, covering 8 major therapeutic fields. Among large multinational pharmaceutical companies, Roche has established and continuously upgraded and improved an end-to-end complete pharmaceutical value industry chain, including early research and development, drug development, production, marketing, and open cooperation, to meet the unmet needs of Chinese patients.